Muscle-targeted nanoparticles strengthen the effects of small-molecule inhibitors in ameliorating sarcopenia.
Nanomedicine (Lond)
; 18(23): 1635-1649, 2023 Oct.
Article
em En
| MEDLINE
| ID: mdl-37909281
ABSTRACT
Background:
Sarcopenia is an aging-related degeneration of muscle mass and strength. Small-molecule inhibitor SW033291 has been shown to attenuate muscle atrophy. Targeted nanodrug-delivery systems can improve the efficacy of small-molecule inhibitors.Methods:
The skeletal muscle cell-targeted nanoparticle was called AP@SW033291, which consisted of SW033291, modular peptide ASSLNIAGGRRRRRG and PEG-DSPE. Nanoparticles were featured with particle size, fluorescence emission spectra and targeting ability. We also investigated their effects on muscle mass and function.Results:
The size of AP@SW033291 was 125.7 nm and it demonstrated targeting effects on skeletal muscle; thus, it could improve muscle mass and muscle function.Conclusion:
Nanoparticle AP@SW033291 could become a potential strategy to strengthen the treatment effects of small-molecule inhibitors in sarcopenia.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Nanopartículas
/
Sarcopenia
Limite:
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Ano de publicação:
2023
Tipo de documento:
Article